Summary
Impetigo, a contagious superficial pyogenic infection of the skin, can be treated orally or topically. Nowadays oral erythromycin is the treatment of choice, although flucloxacillin is preferred in areas where the causative micro-organisms are resistant to erythromycin.
Topical mupirocin ointment has shown itself to be as effective as oral therapy in many cases and is less likely to he associated with unwanted effects.
The availability of 2 forms of therapy — oral and topical — means that treatment can be tailored according to the preferences of the patient. Consequently, drug therapy is more likely to be used appropriately. Arguments for and against the prescribing of each form of therapy are presented.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Antibiotic Guidelines. 5th ed., p. 30, Victorian Medical Postgraduate Foundation, Melbourne, 1987
Becker LE, Tschen E. Common bacterial infections of the skin. Primary Care 10: 397–409, 1983
Carruthers R, Cox GE. Impetigo and its treatment. Medical Journal of Australia 147: 56–57, 1987
Casewell MW, Hill RLR. In vitro activity of mupirocin (‘pseudomonic acid’) against clinical isolates of Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 15: 523–531, 1985
Casewell MW, Hill RLR. Mupirocin (‘pseudomonic acid’) — a promising new topical antimicrobial agent. Journal of Antimicrobial Chemotherapy 19: 1–5, 1987
Dux PH, Fields L, Pollock D. 2% Topical mupirocin versus systemic erythromycin and cloxacillin in primary and secondary skin infections. Current Therapeutic Research 40: 933–940, 1986
Editorial. Topical antibiotics. British Medical Journal 1: 1494, 1977
Editorial. Recurrent staphylococcal furunculosis. Lancet 2: 81–82, 1985
Epstein E. Common skin disorders, p. 110, Medical Economics Company, Oradell, 1979
Geronemus RG, Mertz PM, Eaglstein WH. Wound healing. Archives of Dermatology 115: 1311–1314, 1979
Goodman AS, Gilman LS. The pharmacological basis of therapeutics, 7th ed., p. 966, Macmillan, New York, 1985
Maddin S, Larochelle S, Wilkinson MD, Carey WD, Gratton D, et al. Mupirocin: efficacy and tolerance of a novel, new topical antibiotic vs conventional systemic and topical treatment of primary and secondary skin infections. Contemporary Dermatology 1: 2–7, 1987
Maddox JS, Ware JC, Dillon HC. The natural history of streptococcal skin infection: prevention with topical antibiotics. Journal of the American Academy of Dermatology 13: 207–212. 1985
Marples RR, Kligman AM. Ecological effects of oral antibiotics on the microflora of human skin. Archives of Dermatology 103: 148–153, 1971
Polano MK. Topical skin therapeutics, p. 61. Churchill Livingstone. Edinburgh, 1984
Rahman M, Noble WC, Cookson B, Mupirocin-resistant Staphylococcus aureus. Correspondence, Lancet 2: 387, 1987
Rogers M, Dorman DC, Gapes M, Ly J. A three-year study of impetigo in Sydney. Medical Journal of Australia 147: 63–65, 1987
Ward A, Campoli-Richards DM. Mupirocin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 32: 425–444, 1986
Zaynoun ST, Matta MT, Uwayda MM, Kurban AK. Topical antibiotics in pyodermas. British Journal of Dermatology 90: 331–334. 1974
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carruthers, R. Prescribing Antibiotics for Impetigo. Drugs 36, 364–369 (1988). https://doi.org/10.2165/00003495-198836030-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198836030-00006